Skip to main content

Advertisement

Fig. 4 | BMC Cancer

Fig. 4

From: The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells

Fig. 4

Effect of glutamate transporter inhibition on cellular GSH levels. a Basal intracellular GSH levels were measured as described in Materials and Methods, and normalized to total protein in the samples. b-c Normalized basal GSH levels under control conditions, in HCT116 and LoVo parental and resistant cells after 24 h of treatment with 0.8 μM SN38 or 20 μM oxaliplatin, in absence or presence of DL-TBOA (350 μM) as shown. * p < 0.05 vs untreated control group (n = 5). One-way ANOVA followed by Dunnett post-test

Back to article page